Revenue - Revenue from Licensing Arrangements (Details) $ in Thousands	1 Months Ended			3 Months Ended								12 Months Ended
	Mar. 31, 2022 USD ($)	Mar. 31, 2020 USD ($)	Jun. 30, 2019 USD ($)	Dec. 31, 2022 USD ($)	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Sep. 30, 2021 USD ($)	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($) item
Collaborative Arrangements and Co-Promote Agreement
Total revenue				$ 14,649	$ 12,451	$ 11,050	$ 13,196	$ 14,946	$ 13,194	$ 12,914	$ 14,257	$ 51,346	$ 55,311	$ 71,857
Viatris
Collaborative Arrangements and Co-Promote Agreement
Total revenue		$ 1,500
Upfront payment receivable			$ 18,500
Viatris | Future potential combination products | Development and Sales Milestones
Collaborative Arrangements and Co-Promote Agreement
Total revenue			$ 54,000
Pfizer
Collaborative Arrangements and Co-Promote Agreement
Initial cash payment															$ 10,000
Total revenue	$ 2,500
Number of performance obligations | item															2
Pfizer | Sales milestones
Collaborative Arrangements and Co-Promote Agreement
Initial cash payment												$ 237,500